Today, Australian drug developer NeuClone announced positive preclinical results of its proposed ustekinumab biosimilar referencing Stelara. Ustekinumab is a monoclonal antibody that targets interleukin-12 and -23, and the reference product is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn disease.
Today, Australian drug developer NeuClone announced positive preclinical results of its proposed ustekinumab biosimilar referencing Stelara. Ustekinumab is a monoclonal antibody that targets interleukin-12 and -23, and the reference product is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn disease (CD).
The company announced that it had confirmed the similarity of its molecule to that of the reference product using an X-ray crystallography analysis of both primary amino acid sequence and 3-dimensional folding structure.
NeuClone is developing the proposed product with its partner, Serum Institute of India, and is scaling up to support a planned phase 1 trial of the biosimilar in 2019. Other biosimilars in the drug developer’s pipeline include trastuzumab (referencing Herceptin), which is slated to enter a phase 1 trial in 2018, and preclinical candidates for denosumab (referencing Prolia), palivizumab (referencing Synagis), and adalimumab (referencing Humira), and an additional 5 undisclosed products.
While the market for psoriasis treatments is heating up, with biologic competitors such as guselkumab (Tremfya) and ixekizumab (Taltz) vying for market share, Stelara’s most recently approved indication for the treatment of CD—which the FDA granted in September 2016 on the basis of positive data from 3 pivotal phase 3 studies—helps to buoy sales of the drug for Johnson & Johnson. In the treatment landscape for CD, the option to use an interleukin blocker provides an important alternative for patients who have not had an adequate response to treatment with an anti—tumor necrosis factor therapy.
On the strength of Stelara’s sales in all 3 indications, in its third-quarter 2017 earnings update, Johnson & Johnson, maker of the reference Stelara, reported $800 million in US sales for the quarter, up 42% from the same period in 2016, and $324 million in international sales, up 28.1%.
Another company that has disclosed its efforts to develop a biosimilar of the ustekinumab molecule is German drug maker Formycon, which, together with its partner Aristo Pharma, is in preclinical development with its candidate, FYB202.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.